Leverage the predictive power of the Oncotype DX AR-V7 Nucleus Detect test

The Oncotype DX AR-V7 Nucleus Detect test has the potential to revolutionize how you make treatment decisions for patients with metastatic castration-resistant prostate cancer (mCRPC). Analytically and clinically validated, the AR-V7 Nucleus Detect test is the first assay of its kind to identify—with unparalleled specificity—patients who will not respond to androgen receptor (AR)-targeted therapies, such as abiraterone (e.g., Zytiga®) or enzalutamide (e.g., Xtandi®).*

AR-V7 lab

About the AR-V7 Nucleus Detect test

AR-V7 Nucleus Detect helps you confidently determine when to transition patients to taxane chemotherapy (or other therapies)—giving those patients the opportunity for longer overall survival. Learn more about the test.

Is your patient eligible?

Ordering the AR-V7 Nucleus Detect test is appropriate for patients with mCRPC who have received and failed an AR-targeted therapy, and who are deciding between another AR-targeted therapy and chemotherapy or other treatments. Learn more about when to order the test.

Why nuclear detection?

The AR-V7 Nucleus Detect test detects AR-V7 protein in the nucleus of circulating tumor cells, a process which results in a higher specificity than assays that do not localize AR-V7 identification. Find out more about nuclear detection and why it works.

Clinical evidence

The AR-V7 Nucleus Detect test is predictive of improved overall survival with taxanes versus AR-targeted therapies in nuclear AR-V7+ patients.1,2 See clinical evidence and publications.

How to order the test

The sample for the AR-V7 Nucleus Detect test is obtained by a simple blood draw. Genomic Health makes it easy to order, collect and submit your sample. Get instructions on how to order and perform the test.

REFERENCES

1. Scher et al. JAMA Oncol. 2016.
2. Scher et al. Eur Urol. 2016.

*Zytiga® is a registered trademark of Johnson and Johnson. Xtandi® is a registered trademark of Astellas Pharma, Inc.

 

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™